Computational investigation reveals Picrasidine C as selective PPARα lead: binding pattern, selectivity mechanism and ADME/tox profile

@article{Li2019ComputationalIR,
  title={Computational investigation reveals Picrasidine C as selective PPAR$\alpha$ lead: binding pattern, selectivity mechanism and ADME/tox profile},
  author={Fangfei Li and Han-xun Wang and Ying Wang and Shasha Feng and Baichun Hu and Xiangyu Zhang and Jian Wang and Wei Li and Maosheng Cheng},
  journal={Journal of Biomolecular Structure and Dynamics},
  year={2019},
  volume={38},
  pages={5401 - 5418}
}
Abstract Natural products and their derivatives have been recognized as an important source of therapeutic agents for many years. Previously we isolated a dimeric β-carboline-type alkaloid Picrasidine C from the root of Picrasma quassioides as subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonist. In order to modify this natural product for better affinity and druggability, we investigated a series of properties exhibited by Picrasidine C, such as its binding mode with… 
View on Taylor & Francis
ncbi.nlm.nih.gov
6 Citations
Background Citations
2

6 Citations

Citation Type

Citation Type

Structure-based drug design of peroxisome proliferator-activated receptor gamma inhibitors: ferulic acid and derivatives
Abstract Peroxisome proliferator-activated receptor gamma (PPARγ), ligand-activated transcription factor, is a key modulator of genes considered in diabetes development as well as treatment.…
In silico chemical profiling and identification of neuromodulators from Curcuma amada targeting acetylcholinesterase
TLDR
The present in silico-based characterization demonstrates Curcuma amada as a great source of neuromodulating agents, which can be considered in complementary and alternative medicine and drug development for preventing and treating neurodegenerative disorders.
Integration of Molecular Docking and In Vitro Studies: A Powerful Approach for Drug Discovery in Breast Cancer
TLDR
It is suggested that the integration of molecular docking and in vitro studies can accelerate cancer drug discovery showing a good consistency of the results between the two approaches.
Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1)
TLDR
The present study provides structural information of Mcl-1 inhibitors for next generations of cancer therapeutics through computational and experimental validation approach.
Effects of a Second Local DNA Damage Event on the Toxicity of the Human Carcinogen 4-Aminobiphenyl: A Molecular Dynamics Study of a Damaged DNA Structure.
TLDR
The present work uses quintuplet 0.5 μs MD simulations to understand the structural impact of DNA exposure to the potent bladder carcinogen 4-aminobiphenyl (ABP), which is found in cigarette smoke and select dyes, and results in the widely studied N-linked ABPdG adduct.
Anatomy of noncovalent interactions between the nucleobases or ribose and π-containing amino acids in RNA–protein complexes
TLDR
It is underscoring that RNA–protein π-contacts are ubiquitous in nature, and key to the stability and function of RNA-protein complexes, that the maximum stability is greater for RNA– protein contacts than DNA–protein interactions.

References

SHOWING 1-10 OF 39 REFERENCES
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
TLDR
This is the first report to demonstrate 1 to be a subtype-selective PPARα agonist with potential application in treating metabolic diseases, such as hyperlipidemia, atherosclerosis, and hypercholesterolemia.
Molecular docking, molecular modeling, and molecular dynamics studies of azaisoflavone as dual COX-2 inhibitors and TP receptor antagonists
TLDR
The docking and binding parameters of these new compounds are found to be promising in comparison to those of selective COX-2 inhibitors, such as SC-558 and celecoxib.
Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer’s disease
TLDR
Present study corroborates the pharmacophore-based virtual screening, and finds the compound 6F as a potent Inhibitor of PKC, having therapeutic potential for Alzheimer’s disease.
In Silico Design of Human IMPDH Inhibitors Using Pharmacophore Mapping and Molecular Docking Approaches
TLDR
This study finds two hits that match well the optimal pharmacophore features used in this investigation, and it is found that they form interactions with key residues of IMPDH.
Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations
TLDR
A computational workflow to generate experimental-quality protein–ligand binding models is suggested, overcoming limitations of docking results due to receptor flexibility and incomplete sampling, as a useful starting point for the structure-based lead optimization of novel BRD4(BD1) inhibitors.
In silico exploration of aryl sulfonamide analogs as voltage-gated sodium channel 1.7 inhibitors by using 3D-QSAR, molecular docking study, and molecular dynamics simulations
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
TLDR
Close analogues of the drug comprising selective and dual agonism on RXRs and PPARs that may serve as superior pharmacological tools to study the role and interplay of the nuclear receptors in various pathologies are designed.
Exploring Natural Products as a Source for Antidiabetic Lead Compounds and Possible Lead Optimization.
  • R. A. Khalaf
  • Biology
    Current topics in medicinal chemistry
  • 2016
TLDR
Natural products will remain an attractive source for researchers to explore their therapeutic potential against DM and systematic lead optimization via structural modifications will speed up the generation of potential new clinical candidates for the treatment of type 2 DM.
SAHA-based novel HDAC inhibitor design by core hopping method.
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
An 1,3-oxybenzylglycine based compound 2 (BMS-687453) was discovered to be a potent and selective peroxisome proliferator activated receptor (PPAR) alpha agonist, with an EC(50) of 10 nM for human…
...
1
2
3
4
...